After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project. | On Monday, CSL broke ground on an ...
The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...
The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...
Gov. Pritzker announced that global biotherapeutics firm CSL will invest nearly $1.5 billion to construct a new manufacturing ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. BRADLEY, Ill. — Nearly one week after ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results